Department of Parasitology, Ege University Medical School, Bornova/Izmir 35100, Turkey.
Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
J Med Microbiol. 2011 Jul;60(Pt 7):937-944. doi: 10.1099/jmm.0.030775-0. Epub 2011 Apr 1.
Routine laboratory diagnosis of Pneumocystis jirovecii is currently achieved by PCR in almost all laboratories with sufficient equipment due to its high sensitivity and specificity compared to staining methods. A current issue that limits the reliability and sensitivity of PCR is the degree of inhibition caused by inhibitory substances in respiratory samples. The present study aimed to analyse the degree and frequency of inhibition in real-time PCR detecting P. jirovecii in respiratory specimens submitted to a Pneumocystis pneumonia (PcP) diagnosis laboratory in Ege University Medical School, Turkey. Between July 2009 and December 2010, 76 respiratory specimens [63 bronchoalveolar lavage (BAL) fluid, 10 sputum samples, two tracheal aspiration fluid and one thoracentesis fluid] obtained from 69 PcP-suspected patients were investigated for the presence of P. jirovecii using real-time PCR targeting the cdc2 gene. Of these samples, 42 of the specimens were stained and examined by microscopy according to the request of the clinicians. PCR was positive in 15 specimens in the initial run. Of the remaining 61 samples, 41 of them were negative with positive internal inhibition controls (i.e. true-negative group). The frequency of inhibition in the initial run was 26.31 % (20/76) as determined by spiked negative controls. All of the inhibited samples were resolved after 1 : 2, 1 : 5, 1 : 10 and 1 : 20 dilutions. P. jirovecii was detected by PCR in two inhibited specimens after retesting with diluted samples which were also positive by microscopy. The incidence of P. jirovecii in respiratory specimens was 22.36 % (17/76) as determined by real-time PCR and 7.14 % (3/42) by microscopy. Overall, the incidence of P. jirovecii in respiratory samples was 23.68 % (18/76) as detected by both methods. In conclusion, inclusion of spiked positive controls in each sample and retesting with diluted samples to resolve inhibition increased the reliability of the real-time PCR assay in terms of determining false-negative results and influencing the treatment of the patient. Furthermore, results of the present study determined for the first time the frequency and degree of inhibition in a real-time PCR detecting P. jirovecii in respiratory specimens during routine diagnosis of PcP.
目前,由于其高灵敏度和特异性,几乎所有具备足够设备的实验室都通过 PCR 对耶氏肺孢子菌进行常规实验室诊断。目前,限制 PCR 可靠性和灵敏度的一个问题是呼吸道样本中抑制物质引起的抑制程度。本研究旨在分析土耳其伊兹密尔大学医学院肺孢子菌肺炎(PcP)诊断实验室中实时 PCR 检测呼吸道标本中耶氏肺孢子菌的抑制程度和频率。2009 年 7 月至 2010 年 12 月,对 69 例疑似 PcP 患者的 76 份呼吸道标本(63 份支气管肺泡灌洗液、10 份痰标本、2 份气管抽吸液和 1 份胸腔积液)进行了实时 PCR 检测,以检测 P. jirovecii 的存在,PCR 靶向 cdc2 基因。其中,根据临床医生的要求,对 42 份标本进行染色和显微镜检查。初始运行时,15 份标本 PCR 阳性。在其余 61 份样本中,41 份为阴性,内对照阳性(即真阴性组)。通过添加阴性对照确定初始运行时的抑制频率为 26.31%(20/76)。所有抑制样本经 1:2、1:5、1:10 和 1:20 稀释后均可解决。用稀释后的样本进行重新检测后,PCR 检测到 2 份抑制样本中存在 P. jirovecii,显微镜检查也呈阳性。实时 PCR 检测呼吸道标本中 P. jirovecii 的发生率为 22.36%(17/76),显微镜检查为 7.14%(3/42)。总体而言,两种方法检测呼吸道标本中 P. jirovecii 的发生率为 23.68%(18/76)。总之,在每个样本中加入添加的阳性对照并对抑制样本进行重新检测以解决抑制问题,可提高实时 PCR 检测假阴性结果的可靠性,并影响患者的治疗。此外,本研究首次确定了实时 PCR 检测呼吸道标本中 P. jirovecii 的频率和抑制程度,以便在常规诊断 PcP 时进行检测。